Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-18T20:48:37.721Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms

Published online by Cambridge University Press:  16 April 2020

K Yoshida ,
T Sugita ,
H Higuchi  and
Y Hishikawa
K Yoshida
Affiliation:
Department of NeuropsychiatryAkita University School of Medicine, 1-1-1 Hondo, Akita 010
T Sugita
Affiliation:
Yokote Kosei Hospital, Akita, Japan
H Higuchi
Affiliation:
Department of NeuropsychiatryAkita University School of Medicine, 1-1-1 Hondo, Akita 010
Y Hishikawa
Affiliation:
Department of NeuropsychiatryAkita University School of Medicine, 1-1-1 Hondo, Akita 010
Get access

Summary

The authors examined the effect of tandospirone on tardive dyskinesia (TD) and parkinsonian symptoms in an open study. Tandospirone did not bring about any favourable effect on TD, but it had a good effect on the parkinsonian symptoms.

Keywords

dopamine5-hydroxytryptamineparkinsonian symptomstandospironetardive dyskinesia
Type
Case Report
Information
European Psychiatry , Volume 13 , Issue 8 , December 1998 , pp. 421 - 422
Copyright
Copyright © Elsevier, Paris 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Goff, DCMidha, KKBrotman, AWMcCormick, SWaites, MAmico, ETAn open trial of buspirone added to neuroleptics in schizophrenic patients J Clin Psychopharmacol 1991; 11: 193–197CrossRefGoogle ScholarPubMed
Haggstrom, JEGunne, LMCarlsson, AWikstrom, HAntidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias J Neural Transm 1983; 58: 135–142CrossRefGoogle ScholarPubMed
Hamik, AOksenberg, DFischette, CPeroutka, SJAnalysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites Biol Psychiatry 1990; 28: 99–109CrossRefGoogle ScholarPubMed
Kapur, SRemington, GSerotonin-dopamine interaction and its relevance to schizophrenia Am J Psychiatry 1996; 153: 466–476Google Scholar
McMillen, BAComparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission J Neural Transm 1985; 64: 1–12CrossRefGoogle ScholarPubMed
Moss, LENeppe, VMDrevets, WCBuspirone in the treatment of tardive dyskinesia J Clin Psychopharmacol 1993; 13: 204–209CrossRefGoogle ScholarPubMed
Riblet, LATaylor, DPEison, MSStanton, HCPharmacology and neurochemistry of buspirone J Clin Psychiatry 1982; 43: 11–18Google ScholarPubMed
Schooler, NRKane, JMResearch diagnoses for tardive dyskinesia [letter] Arch Gen Psychiatry 1982; 39: 486–487Google Scholar
Submit a response

Comments

No Comments have been published for this article.